Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Watcher's Thread / Pix of the Week (POW) -- Ignore unavailable to you. Want to Upgrade?

To: Stock Watcher who wrote (20672)	12/5/1999 4:59:00 PM
From: SouthFloridaGuy	Read Replies (3) \| Respond to of 52051

POW is NTPL for sure. No other stock need be looked at by thread.

To: Stock Watcher who wrote (20672)	12/5/1999 9:22:00 PM
From: DENNIS TULLY	Read Replies (1) \| Respond to of 52051

CLTR Back in the news again. This should show some action this week. 12/04/99 - Coulter's lymphoma drug shows promising results -------------------------------------------------------------------------------- NEW ORLEANS, Dec 4 (Reuters) - Bexxar, Coulter Pharmaceutical Inc.'s (CLTR.O) drug for treating lymphoma, showed promising results in Phase II studies when used in combination with conventional chemotherapy, according to a study on Saturday. The study by Cornell University showed that all patients with low grade non-Hodgkin's lymphoma went either into complete remission or saw partial response when on a regime of chemotherapy agent fludarabine followed by Bexxar. The Cornell study, funded by Coulter, said that following an initial five week treatment with only fludarabine, 14 percent of patients, or two out of 14, went into complete remission. Three months into the study, following treatment with Bexxar, 43 percent of patients went into complete remission. After about six months, 71 percent of patients had the same result. The remaining patients who did not go into complete remission saw a reduction in the signs and symptoms of lymphoma, such as a reduction in the number of cancer cells. The study, which was released at the annual American Society of Hematology in New Orleans, included only patients who had never been treated for their disease. Last summer, Coulter applied for U.S. marketing approval for Bexxar as a stand alone treatment for patients with low-grade lymphoma who have failed other therapies or who have responded and then relapsed. The approval process has been delayed because of modifications in the marketing applications requested by the U.S. Food and Drug Administration. Saturday's study is not related to the modifications request by the FDA. Bexxar is to be co-marketed with SmithKline Beecham Plc (SB.L). REUTERS Rtr 10:45 12-04-99